Evidence map›Paper›PMID 25531281›Full record

Trial reportBone marrow transplantation2015

Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.

H Nakasone, T Fukuda, J Kanda, T Mori, S Yano, T Kobayashi, K Miyamura, T Eto, H Kanamori, K Iwato and 8 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Allogeneic Transplant and Gene Therapy: Evolving Toward a Cure.Hematology/oncology clinics of North America · 2022
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

H Nakasone1] Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA [2] Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
T FukudaStem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
J KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
T MoriDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
S YanoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
T KobayashiHematology Division, Tokyo Metropolitan Cancer & Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
K MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
T EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
H KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
K IwatoDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors, Hiroshima, Japan.
N UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
S MoriDivision of Hematology and Oncology, St Luke's International Hospital, Tokyo, Japan.
T Nagamura-InoueDepartment of Cell Processing and Transfusion, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
T IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Y Atsuta1] Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan [2] Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.
T TeshimaDepartment of Hematology, Hokkaido University Graduate School of Medical Science, Sapporo, Japan.
M MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
GVHD working group of the Japan Society of Hematopoietic Cell Transplantation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of the conditioning intensity and TBI on acute GVHD (aGVHD) is still a matter of debate. We analyzed 6848 adult recipients who received allogeneic hematopoietic cell transplants (HCT) between 2006 and 2011 in Japan. The subjects were divided into groups who had received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), either with or without TBI. There was a significant difference in the incidence of aGVHD 2-4 among the different conditioning types: 39% in TBI-MAC, 35% in TBI-RIC and 32% in both no-TBI MAC and no-TBI-RIC (P<0.001). In a multivariate analysis, TBI-MAC, but not no-TBI MAC, was significantly associated with an increased risk of aGVHD 2-4 (hazard ratio (HR) 1.33, P<0.01), whereas TBI-RIC was associated with an increased risk of GVHD 3-4 (HR 1.36, P=0.048). TBI-MAC and TBI-RIC were significantly associated with skin and gastrointestinal aGVHD. Subgroup analyses demonstrated that not only TBI-MAC, but also TBI-RIC, was significantly associated with aGVHD 2-4 in older patients. Furthermore, high-dose TBI only had an adverse impact on aGVHD 2-4 in HLA-matched HCT. Impacts of intensity and TBI on aGVHD differ by patient backgrounds, and this difference should be considered to establish a risk-adapted strategy for the prevention of aGVHD.

Indexed as

Hematopoietic Stem Cell TransplantationRegistriesTransplantation ConditioningAcute DiseaseAdolescentAdultAllograftsFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansMaleMiddle AgedRisk Factors

Identifiers

PMID25531281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.